Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2008

01-06-2008 | Breast Oncology

Timing of Surgical Intervention for the Intact Primary in Stage IV Breast Cancer Patients

Authors: Roshni Rao, MD, Lei Feng, MS, Henry M. Kuerer, MD, S. Eva Singletary, MD, Isabelle Bedrosian, Kelly K. Hunt, MD, Merrick I. Ross, MD, Gabriel N. Hortobagyi, MD, Barry W. Feig, MD, Frederick C. Ames, MD, Gildy V. Babiera, MD

Published in: Annals of Surgical Oncology | Issue 6/2008

Login to get access

Abstract

Background

Recent studies demonstrate improved progression-free survival (PFS) and improved overall survival (OS) with extirpation of the primary tumor in breast cancer patients who present with metastatic disease at initial diagnosis. The subset of patients who would most benefit from surgery remains unclear. This study evaluates the pathological attributes and optimum timing for surgery in patients who present with stage IV breast cancer and an intact primary.

Methods

Retrospective, single-institution review of all breast cancer patients between 1997 and 2002 presenting with an intact tumor and synchronous metastatic disease. Information collected included: demographics, tumor characteristics, metastatic sites, type/timing of surgery, and radiation/systemic therapy received. Patients initiated treatment within 3 months of their diagnosis. Patients were divided into three groups based on time interval from diagnosis date to surgery date. Disease progression and vital status at last follow-up were evaluated. Analysis of metastatic PFS (defined by progression of systemic disease) benefit in relation to surgical timing was performed.

Results

Multivariate analysis revealed patients having only one site of metastasis, negative margins, and Caucasian race had improved PFS. Further analysis revealed non-Caucasian patients more often underwent surgical intervention for palliation versus surgery for curative intent, possibly explaining their worse outcome. Patients who underwent surgery in the 3–8.9 month or later period had improved metastatic PFS. Conclusions: Surgical extirpation of the primary tumor in patients with synchronous stage IV disease is associated with improved metastatic PFS when performed more than 3 months after diagnosis. Resection should be planned with the intent of obtaining negative margins.
Literature
1.
Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002; 132:620–7PubMedCrossRef
2.
Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006; 13:776–82PubMedCrossRef
3.
Duffaud F, Therasse P. New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 2000; 87:881–6PubMed
4.
Singletary SE, Allred C, Ashley C, et al., Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am 2003; 83:803–19PubMedCrossRef
5.
Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14 year period. J Clin Oncol 2004; 22:3302–8PubMedCrossRef
6.
Polite BN, Olopade OI. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med 2005; 48(Suppl):166–75
7.
Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347:567–75. PubMedCrossRef
8.
Kinoshita T, Takasugi M, Iwamoto E, et al. Sentinel lymph node biopsy examination for breast cancer patients with clinically negative axillary lymph nodes after neoadjuvant chemotherapy. Am J Surg 2006; 191:225–9PubMedCrossRef
9.
Norton L. Conceptual and practical implications of breast tissue geometry: toward a more effective, less toxic therapy. The Oncologist 2005; 10:370–81PubMedCrossRef
Metadata
Title
Timing of Surgical Intervention for the Intact Primary in Stage IV Breast Cancer Patients
Authors
Roshni Rao, MD
Lei Feng, MS
Henry M. Kuerer, MD
S. Eva Singletary, MD
Isabelle Bedrosian
Kelly K. Hunt, MD
Merrick I. Ross, MD
Gabriel N. Hortobagyi, MD
Barry W. Feig, MD
Frederick C. Ames, MD
Gildy V. Babiera, MD
Publication date
01-06-2008
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 6/2008
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-9830-4

Other articles of this Issue 6/2008

Annals of Surgical Oncology 6/2008 Go to the issue

Bone and Soft Tissue Sarcomas

Raloxifene Can Reduce Giant Cell Tumor Recurrence: A New Adjuvant Therapy

Gastrointestinal Oncology

Esophageal Cancers with Synchronous or Antecedent Head and Neck Cancers: A More Formidable Challenge?

Laboratory Research

Increased Expression of Fractalkine is Correlated with a Better Prognosis and an Increased Number of Both CD8+ T Cells and Natural Killer Cells in Gastric Adenocarcinoma

Breast Oncology

Screening for Recurrences in Patients Treated with Breast-Conserving Surgery: Is there a Role for MRI?

Endocrine Tumors

The Influence of Surgical Approach on Quality of Life After Parathyroid Surgery

Gastrointestinal Oncology

Most Pancreatic Cancer Resections are R1 Resections